台股 » 個股 » 浩鼎 » 籌碼相關 » 融資融券與借券

浩鼎

(4174)
可現股當沖
  • 股價
    62.8
  • 漲跌
    ▲1.0
  • 漲幅
    +1.62%
  • 成交量
    497
  • 產業
    上櫃 生技醫療類股
  • 217人加入追蹤

    立即追蹤

  • 本地時間:13:35(已收盤)

     
浩鼎 (4174) 融資融券與借券

股票投資新手教室: 一分鐘搞懂「融資融券」

浩鼎 (4174) 融資融券與借券

浩鼎 (4174) 近三十日融資融券與借券賣出
日期 融資 融券 資券互抵(張) 資券當沖(%) 券資比(%) 價格 比例 成交量
增加 餘額 使用率% 增加 餘額 使用率%
03/28272,3264.06-120000.0962.81.62%497
03/27-62,2994.01130.0120.370.1361.80.98%539
03/26-12,3054.02020000.0961.2-1.77%433
03/25132,3064.02-120000.0962.30.48%457
03/2222,2934030.0110.360.13621.31%275
03/2122,2913.99030.01000.1361.2-0.16%379
03/20-92,2893.99030.01000.1361.3-0.97%344
03/19202,2984.01-130.01000.1361.9-0.64%670
03/18-12,2783.97-340.01000.1862.32.81%690
03/15342,2793.97370.01000.3160.61.00%489
03/14-112,2453.91-140.0110.120.1860-0.99%820
03/13-12,2563.93250.01000.2260.6-4.27%954
03/1252,2573.93030.01000.1363.3-0.78%804
03/11-162,2523.93130.01000.1363.8-0.31%260
03/08182,2683.95020000.0964-1.69%631
03/0752,2503.92020000.0965.1-1.51%834
03/06112,2453.91020000.0966.1-0.15%262
03/0552,2343.89020000.0966.2-0.15%354
03/04-1052,2293.89020000.0966.30.00%349
03/0152,3344.07020000.0966.3-0.90%360
02/2982,3294.06020000.0966.9-0.89%515
02/27352,3214.05020000.0967.5-0.74%477
02/26-432,2863.99020000.09682.87%771
02/23522,3294.0602020.260.0966.1-1.20%769
02/22432,2773.97020000.0966.9-0.45%515
02/21-82,2343.89020000.0967.2-1.47%565
02/20112,2423.91020000.0968.2-0.87%301
02/19-152,2313.8902020.590.0968.80.15%341
02/16142,2463.9202010.30.0968.71.03%331
02/15172,2323.89-320000.09681.04%392
日期 融券 借券賣出 價格 比例 成交量
買進 賣出 增加 餘額 使用率% 賣出 還券 調整 增加 餘額
03/28100-12@Limit202522035,74462.81.62%497
03/2701013@Limit20.011815035,74161.80.98%539
03/2600002@Limit202524015,73861.2-1.77%433
03/25100-12@Limit20111290-1185,73762.30.48%457
03/2200003@Limit20.0112130-15,855621.31%275
03/2100003@Limit20.012240-225,85661.2-0.16%379
03/2000003@Limit20.012120-105,87861.3-0.97%344
03/19100-13@Limit20.0148290195,88861.9-0.64%670
03/18300-34@Limit20.019390-305,86962.32.81%690
03/1503037@Limit20.013100315,89960.61.00%489
03/14210-14@Limit20.013100315,86860-0.99%820
03/1302025@Limit20.0180110695,83760.6-4.27%954
03/1200003@Limit20.01120001205,76863.3-0.78%804
03/1101013@Limit20.016720655,64863.8-0.31%260
03/0800002@Limit20101001015,58364-1.69%631
03/0700002@Limit20122001225,48265.1-1.51%834
03/0600002@Limit207650715,36066.1-0.15%262
03/0500002@Limit206110605,28966.2-0.15%354
03/0400002@Limit203500355,22966.30.00%349
03/0100002@Limit2050100405,19466.3-0.90%360
02/2900002@Limit20123001235,15466.9-0.89%515
02/2700002@Limit206230595,03167.5-0.74%477
02/2600002@Limit206400644,972682.87%771
02/2300002@Limit20128101274,90866.1-1.20%769
02/2200002@Limit2059440154,78166.9-0.45%515
02/2100002@Limit20102101014,76667.2-1.47%565
02/2000002@Limit2034170174,66568.2-0.87%301
02/1900002@Limit204270354,64868.80.15%341
02/1600002@Limit203200324,61368.71.03%331
02/15300-32@Limit208100814,581681.04%392
日期 當沖成交張數 買進成交金額 賣出成交金額 現股當沖率(%) 平均盈虧
03/28935,827,3005,846,80018.71209.68
03/271086,619,1006,639,50020.04188.89
03/26462,844,3002,847,80010.6276.09
03/25945,882,5005,894,10020.57123.4
03/22563,469,0003,474,60020.36100
03/21875,340,9005,333,90022.96-80.46
03/20835,129,1005,125,70024.13-40.96
03/1917010,725,60010,724,40025.37-7.06
03/181086,683,6006,657,80015.65-238.89
03/151156,980,8006,981,40023.525.22
03/141126,717,3006,736,80013.66174.11
03/13996,118,2006,138,10010.38201.01
03/121207,616,5007,654,20014.93314.17
03/11523,317,3003,323,30020115.38
03/08956,183,3006,139,30015.06-463.16
03/071238,045,3008,075,60014.75246.34
03/06432,858,6002,856,30016.41-53.49
03/05392,590,0002,588,70011.02-33.33
03/04553,647,8003,649,20015.7625.45
03/01412,737,3002,734,80011.39-60.98
02/29553,667,6003,665,40010.68-40
02/271067,140,4007,149,80022.2288.68
02/261117,440,6007,502,30014.4555.86
02/231429,481,3009,447,70018.47-236.62
02/22483,201,6003,215,3009.32285.42
02/21362,434,2002,438,4006.37116.67
02/20191,300,9001,299,1006.31-94.74
02/19563,868,7003,873,00016.4276.79
02/16271,845,3001,853,6008.16307.41
02/15563,802,1003,802,00014.29-1.79
AACR 2024年會 浩鼎將發表ADC藥物臨床前數據Anue鉅亨-10天前
浩鼎乳癌針劑新藥三期臨床期中分析 獲可繼續執行建議Anue鉅亨-2024/01/31
浩鼎新任董座梁賡義:借助官學人脈助公司推動生物統計發展Anue鉅亨-2024/01/22
浩鼎 相關文章